445 related articles for article (PubMed ID: 8864278)
1. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
3. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
[TBL] [Abstract][Full Text] [Related]
4. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
[TBL] [Abstract][Full Text] [Related]
5. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
Dong L; Pu PY; Wang H; Wang GX; Kang CS; Jiao DR
Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.
Cheng Y; Ng HK; Ding M; Zhang SF; Pang JC; Lo KW
J Neuropathol Exp Neurol; 1999 Feb; 58(2):120-8. PubMed ID: 10029095
[TBL] [Abstract][Full Text] [Related]
7. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.
Reifenberger J; Ring GU; Gies U; Cobbers L; Oberstrass J; An HX; Niederacher D; Wechsler W; Reifenberger G
J Neuropathol Exp Neurol; 1996 Jul; 55(7):822-31. PubMed ID: 8965097
[TBL] [Abstract][Full Text] [Related]
8. Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
Gil-Benso R; Lopez-Gines C; Benito R; López-Guerrero JA; Callaghan RC; Pellín A; Roldán P; Cerdá-Nicolas M
Clin Neuropathol; 2007; 26(5):224-31. PubMed ID: 17907599
[TBL] [Abstract][Full Text] [Related]
9. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
10. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
11. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
Sure U; Rüedi D; Tachibana O; Yonekawa Y; Ohgaki H; Kleihues P; Hegi ME
J Neuropathol Exp Neurol; 1997 Jul; 56(7):782-9. PubMed ID: 9210874
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
Das A; Tan WL; Teo J; Smith DR
J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
[TBL] [Abstract][Full Text] [Related]
13. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
Biernat W; Kleihues P; Yonekawa Y; Ohgaki H
J Neuropathol Exp Neurol; 1997 Feb; 56(2):180-5. PubMed ID: 9034372
[TBL] [Abstract][Full Text] [Related]
14. Primary and secondary glioblastomas: from concept to clinical diagnosis.
Kleihues P; Ohgaki H
Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
[TBL] [Abstract][Full Text] [Related]
15. Sporadic p53 mutations and absence of ras mutations in glioblastomas.
Gömöri E; Dóczi T; Pajor L; Matolcsy A
Acta Neurochir (Wien); 1999; 141(6):593-9. PubMed ID: 10929724
[TBL] [Abstract][Full Text] [Related]
16. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
17. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
Simmons ML; Lamborn KR; Takahashi M; Chen P; Israel MA; Berger MS; Godfrey T; Nigro J; Prados M; Chang S; Barker FG; Aldape K
Cancer Res; 2001 Feb; 61(3):1122-8. PubMed ID: 11221842
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic alterations in glioblastomas with oligodendroglial component.
Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
[TBL] [Abstract][Full Text] [Related]
19. Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations.
Watanabe T; Nobusawa S; Lu S; Huang J; Mittelbronn M; Ohgaki H
J Neuropathol Exp Neurol; 2009 Feb; 68(2):210-5. PubMed ID: 19151620
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
